On November 24, the Great hall of the Civic Chamber of the Russian Federation hosted the ceremony to award the winners of the 6th National Award “PRIORITY-2020” in the field of effective use of advanced technologies.
For the second year in a row, NANOLEK has won this prestigious award, this year in the nomination “Localization of production” for HUNTERASE® - the drug used in the treatment of Hunter syndrome.”
The award is given for achievements in the development, implementation and promotion of advanced domestic technologies in all industries and IT areas. The year 2020 saw more than 30 nominations, and more than 70 companies from different industries that became nominees: IT, medical science, telecommunications, construction, pharmaceuticals, transport, logistics, etc. The contest is powered by the industry-related ministries and departments of Russia – the Ministry of Industry and Trade, the Ministry of Agriculture, Ministry of Energy, Ministry of Communications as well as public associations: Russian Union of Industrialists and Entrepreneurs, Russian Сhamber of Commerce and Industry, “Delovaya Rossiya”, Federal Customs Service and Federal Antimonopoly Service.
“The “Priority Award” is a socially significant event, it drives the development of production of domestic high-tech products and helps enhance competitiveness of our industry in the domestic and foreign markets,“ said Yuri Borisov, Deputy Prime Minister of the Russian Federation.
“The “Priority 2.0” national award is a landmark event for the real economy, for companies that do not rest today on their laurels amidst challenging economic conditions, develop production facilities and technology and achieve competitive advantages in the domestic and global markets,“ said Vitaly Rasnitsyn, Chairman of the Award Organizing Committee.
Elena Stukun, Deputy General Director for Sales at Nanolek, took the occasion during the award ceremony to thank the organizers and the expert council for evaluating highly the Company’s efforts:
“NANOLEK specializes in the production of import-substituting and innovative drugs for the prevention and treatment of socially significant diseases. Today we received an award for the original drug Hunterase® used to treat the orphan disease mucopolysaccharidosis type II. To date, we have completed the first stage of production localization in the Russian Federation.
An amazing work done by our team is an evidence that we are able to produce innovative drugs meeting all international standards in our country. Dear colleagues, I would like to express my gratitude towards our team for their achievements. We in turn will continue to do our best for the development of the Russian pharmaceutical industry and draw attention to the issues of orphan diseases.”
About MPS II
Mucopolysaccharidosis type II (MPS II) is a severe, disabling disease. Since January 1, 2019, MPS II has been on the list of 14 high-cost nosologies (VZN). In February 2019, Hunterase® was included in the standard regimen to treat Hunter syndrome. NANOLEK is currently the only Russian company that maintains a domestic facility in Russia to produce a drug used for the treatment of the disease. The NANOLEK facility that produces Hunterase® is located on the biopharmaceutical complex in the Kirov region. This guarantees that medicines are supplied uninterrupted to patients in Russia suffering from this rare disease. Domestic production also allows to lessen the financial burden on the federal budget since Hunterase® is more than 20% cheaper as compared to the alternative enzyme replacement therapy.